Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)
Taiwan · Delayed Price · Currency is TWD 32.85
+0.35 (1.08%)
May 29, 2026, 1:30 PM CST
Nang Kuang Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,112 | 2,162 | 2,200 | 2,150 | 1,940 | 1,780 | |
Revenue Growth (YoY) | -6.15% | -1.71% | 2.31% | 10.81% | 9.01% | 1.44% |
Cost of Revenue | 1,376 | 1,393 | 1,452 | 1,395 | 1,246 | 1,186 |
Gross Profit | 736.53 | 768.86 | 747.79 | 755.56 | 694.9 | 594.47 |
Selling, General & Admin | 306.65 | 302.62 | 270.88 | 252.78 | 227.29 | 204.05 |
Research & Development | 166.66 | 170.58 | 169.36 | 164.11 | 143.81 | 133.97 |
Operating Expenses | 473.31 | 473.19 | 437.57 | 495.72 | 373.24 | 339.99 |
Operating Income | 263.22 | 295.67 | 310.22 | 259.84 | 321.67 | 254.48 |
Interest Expense | -8.66 | -8.59 | -5.53 | -7.18 | -4.84 | -3.53 |
Interest & Investment Income | 3.2 | 3.12 | 3 | 10.64 | 2.69 | 3.46 |
Currency Exchange Gain (Loss) | 4.53 | 4.53 | 8.6 | 4.1 | 8.79 | -11.98 |
Other Non Operating Income (Expenses) | -4.31 | 11.18 | 9.82 | 9.44 | 9.25 | 10.04 |
EBT Excluding Unusual Items | 257.98 | 305.9 | 326.11 | 276.85 | 337.56 | 252.47 |
Gain (Loss) on Sale of Investments | -14.3 | -14.3 | -23.07 | -1.85 | 73.11 | 0.14 |
Gain (Loss) on Sale of Assets | -0.09 | -0.09 | 0.17 | 6.1 | -0.05 | -0.15 |
Legal Settlements | -0.37 | -0.37 | - | -67.43 | - | -22.96 |
Other Unusual Items | - | - | - | 0 | - | 5.26 |
Pretax Income | 243.22 | 291.14 | 303.2 | 213.68 | 410.63 | 234.76 |
Income Tax Expense | 39.28 | 47.2 | 59.8 | 15.27 | 58.63 | 38.65 |
Earnings From Continuing Operations | 203.95 | 243.95 | 243.41 | 198.41 | 352 | 196.11 |
Minority Interest in Earnings | 1.01 | 0.47 | - | - | - | - |
Net Income | 204.95 | 244.41 | 243.41 | 198.41 | 352 | 196.11 |
Net Income to Common | 204.95 | 244.41 | 243.41 | 198.41 | 352 | 196.11 |
Net Income Growth | -21.39% | 0.41% | 22.68% | -43.63% | 79.49% | 6.93% |
Shares Outstanding (Basic) | 101 | 101 | 101 | 101 | 101 | 101 |
Shares Outstanding (Diluted) | 101 | 101 | 101 | 101 | 101 | 101 |
Shares Change (YoY) | -0.29% | 0.02% | 0.10% | -0.08% | -0.01% | 0.03% |
EPS (Basic) | 2.03 | 2.42 | 2.41 | 1.96 | 3.49 | 1.94 |
EPS (Diluted) | 2.03 | 2.41 | 2.40 | 1.96 | 3.48 | 1.94 |
EPS Growth | -21.16% | 0.42% | 22.45% | -43.68% | 79.38% | 7.18% |
Free Cash Flow | 41.65 | 186.25 | -58.17 | 45.1 | 275.35 | 400.58 |
Free Cash Flow Per Share | 0.41 | 1.84 | -0.57 | 0.45 | 2.72 | 3.96 |
Dividend Per Share | - | - | 1.600 | 2.000 | 2.300 | 1.800 |
Dividend Growth | - | - | -20.00% | -13.04% | 27.78% | 12.50% |
Gross Margin | 34.87% | 35.56% | 33.99% | 35.14% | 35.81% | 33.40% |
Operating Margin | 12.46% | 13.67% | 14.10% | 12.08% | 16.58% | 14.30% |
Profit Margin | 9.70% | 11.30% | 11.06% | 9.23% | 18.14% | 11.02% |
Free Cash Flow Margin | 1.97% | 8.61% | -2.64% | 2.10% | 14.19% | 22.50% |
EBITDA | 443.99 | 478.06 | 492.34 | 440.76 | 496.66 | 433.33 |
EBITDA Margin | 21.02% | 22.11% | 22.38% | 20.50% | 25.59% | 24.34% |
D&A For EBITDA | 180.77 | 182.39 | 182.12 | 180.92 | 174.99 | 178.85 |
EBIT | 263.22 | 295.67 | 310.22 | 259.84 | 321.67 | 254.48 |
EBIT Margin | 12.46% | 13.67% | 14.10% | 12.08% | 16.58% | 14.30% |
Effective Tax Rate | 16.15% | 16.21% | 19.72% | 7.15% | 14.28% | 16.46% |